Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression

 

 Buy Article Permissions and Reprints

Summary

Vascular leakage due to compromised integrity of the endothelial barrier is closely associated with brain damage in several neurological disorders, including ischaemic stroke. Saxatilin, a snake venom disintegrin containing the Arg-Gly-Asp (RGD) motif, exerts thrombolytic and antiplatelet effects by interacting with multiple integrins on platelets. Integrin signalling is indispensable for regulation of endothelial permeability. Saxatilin may play a role in vascular leakage after ischaemia because it has high affinity for endothelial integrins. Here, we determined whether Fc-saxatilin, an Fc-fusion protein of saxatilin, could prevent vascular leakage under hypoxic or ischaemic conditions. In mouse brain microvascular endothelial cells, hypoxia increased the permeability to FITC-dextran, and this effect was attenuated by Fc-saxatilin treatment. Fc-saxatilin also blocked vascular leakage of Evans Blue in the ischaemic brain induced by middle cerebral artery occlusion in mice. Furthermore, the expression of occludin, a tight junction protein, was reduced by hypoxia in endothelial cells. This downregulation of occludin was attenuated by Fc-saxatilin treatment. We also determined the activity of matrix metalloproteinases (MMPs) 2 and 9 because they are implicated in the degradation of occludin and of the microvascular basal lamina. Hypoxia increased MMP-9 activity, and this increase was attenuated by Fc-saxatilin treatment. Fc-saxatilin specifically bound to integrin αvβ3 of the endothelial cells and inhibited hypoxia-induced activation of FAK, a downstream signalling molecule in integrin-dependent signal transduction. Taken together, these results provide new insights into the mechanism via which Fc-saxatilin, as an integrin antagonist, prevents vascular leakage under ischemic conditions by regulating occludin expression in endothelial tight junctions.

Supplementary Material to this article is available online at www.thrombosis-online.com.

• References

• 1 Hong SY, Koh YS, Chung KH. et al. Snake venom disintegrin, saxatilin, inhibits platelet aggregation, human umbilical vein endothelial cell proliferation, and smooth muscle cell migration. Thromb Res 2002; 105: 79-86.
  CrossrefPubMedGoogle Scholar
• 2 Hong SY, Sohn YD, Chung KH. et al. Structural and functional significance of disulfide bonds in saxatilin, a 7.7 kDa disintegrin. Biochem Biophys Res Commun 2002; 293: 530-536.
  CrossrefPubMedGoogle Scholar
• 3 Kwon I, Hong SY, Kim YD. et al. Thrombolytic effects of the snake venom disintegrin saxatilin determined by novel assessment methods: a FeCl3-induced thrombosis model in mice. PloS One 2013; 08: e81165.
  CrossrefPubMedGoogle Scholar
• 4 Phillips DR, Charo IF, Parise LV. et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-843.
  PubMedGoogle Scholar
• 5 Abou-Chebl A, Bajzer CT, Krieger DW. et al. Multimodal therapy for the treatment of severe ischaemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. Stroke 2005; 36: 2286-2288.
  CrossrefPubMedGoogle Scholar
• 6 Eckert B, Koch C, Thomalla G. et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST): results of a multicenter study. Stroke 2005; 36: 1160-1165.
  CrossrefPubMedGoogle Scholar
• 7 Seitz RJ, Meisel S, Moll M. et al. The effect of combined thrombolysis with rtPA and tirofiban on ischaemic brain lesions. Neurology 2004; 62: 2110-2112.
  CrossrefPubMedGoogle Scholar
• 8 Jang YJ, Jeon OH, Kim DS. Saxatilin, a snake venom disintegrin, regulates platelet activation associated with human vascular endothelial cell migration and invasion. J Vasc Res 2007; 44: 129-137.
  CrossrefPubMedGoogle Scholar
• 9 Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-571.
  CrossrefPubMedGoogle Scholar
• 10 Nisato RE, Tille JC, Jonczyk A. et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 06: 105-119.
  CrossrefPubMedGoogle Scholar
• 11 Byzova TV, Goldman CK, Pampori N. et al. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000; 06: 851-860.
  PubMedGoogle Scholar
• 12 Suzuma K, Takagi H, Otani A. et al. Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells. Invest Ophthalmol Visual Sci 1998; 39: 1028-1035.
  PubMedGoogle Scholar
• 13 Sloan EK, Pouliot N, Stanley KL. et al. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006; 08: R20.
  CrossrefPubMedGoogle Scholar
• 14 Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 08: 724-730.
  CrossrefPubMedGoogle Scholar
• 15 Abumiya T, Lucero J, Heo JH. et al. Activated microvessels express vascular endothelial growth factor and integrin alpha(v)beta3 during focal cerebral ischaemia. J Cerebral Blood Flow Metabol 1999; 19: 1038-1050.
  CrossrefPubMedGoogle Scholar
• 16 Okada Y, Copeland BR, Hamann GF. et al. Integrin alphavbeta3 is expressed in selected microvessels after focal cerebral ischaemia. Am J Pathol 1996; 149: 37-44.
  PubMedGoogle Scholar
• 17 Tagaya M, Haring HP, Stuiver I. et al. Rapid loss of microvascular integrin expression during focal brain ischaemia reflects neuron injury. J Cerebral Blood Flow Metabol 2001; 21: 835-846.
  CrossrefPubMedGoogle Scholar
• 18 Shimamura N, Matchett G, Solaroglu I. et al. Inhibition of integrin alphavbeta3 reduces blood-brain barrier breakdown in focal ischaemia in rats. J Neurosci Res 2006; 84: 1837-1847.
  CrossrefPubMedGoogle Scholar
• 19 Shimamura N, Matchett G, Yatsushige H. et al. Inhibition of integrin alphavbeta3 ameliorates focal cerebral ischaemic damage in the rat middle cerebral artery occlusion model. Stroke 2006; 37: 1902-1909.
  CrossrefPubMedGoogle Scholar
• 20 Abumiya T, Fitridge R, Mazur C. et al. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischaemia. Stroke 2000; 31: 1402-1410.
  CrossrefPubMedGoogle Scholar
• 21 Robinson SD, Reynolds LE, Wyder L. et al. Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscl Thromb Vasc Biol 2004; 24: 2108-2114.
  CrossrefPubMedGoogle Scholar
• 22 Bauer AT, Burgers HF, Rabie T. et al. Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cerebral Blood Flow Metabol 2010; 30: 837-848.
  CrossrefPubMedGoogle Scholar
• 23 Yang Y, Estrada EY, Thompson JF. et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischaemia in rat. J Cerebral Blood Flow Metabol 2007; 27: 697-709.
  CrossrefPubMedGoogle Scholar
• 24 Kago T, Takagi N, Date I. et al. Cerebral ischaemia enhances tyrosine phosphorylation of occludin in brain capillaries. Biochem Biophys Res Commun 2006; 339: 1197-1203.
  CrossrefPubMedGoogle Scholar
• 25 Lohmann C, Krischke M, Wegener J. et al. Tyrosine phosphatase inhibition induces loss of blood-brain barrier integrity by matrix metalloproteinase-dependent and -independent pathways. Brain Res 2004; 995: 184-196.
  CrossrefPubMedGoogle Scholar
• 26 Takenaga Y, Takagi N, Murotomi K. et al. Inhibition of Src activity decreases tyrosine phosphorylation of occludin in brain capillaries and attenuates increase in permeability of the blood-brain barrier after transient focal cerebral ischaemia. J Cerebral Blood Flow Metabol 2009; 29: 1099-1108.
  CrossrefPubMedGoogle Scholar
• 27 Chen XL, Nam JO, Jean C. et al. VEGF-induced vascular permeability is mediated by FAK. Develop Cell 2012; 22: 146-157.
  CrossrefPubMedGoogle Scholar
• 28 Jean C, Chen XL, Nam JO. et al. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol 2014; 204: 247-263.
  CrossrefPubMedGoogle Scholar
• 29 Wu MH. Endothelial focal adhesions and barrier function. J Physiol 2005; 569: 359-366.
  CrossrefPubMedGoogle Scholar
• 30 Jin YJ, Park I, Hong IK. et al. Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin alpha(5)beta(1)/alpha(v)beta(3)-dependent Akt, ERK and JNK signalling pathways in human umbilical vein endothelial cells. Cell Signal 2011; 23: 125-134.
  CrossrefPubMedGoogle Scholar
• 31 Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009; 08: 205-216.
  CrossrefPubMedGoogle Scholar
• 32 Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischaemia. Glia 2005; 50: 329-339.
  CrossrefPubMedGoogle Scholar
• 33 Kilkenny C, Browne WJ, Cuthill IC. et al. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharmacol Pharmacotherap 2010; 01: 94-99.
  PubMedGoogle Scholar
• 34 Fisher M, Feuerstein G, Howells DW. et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-2250.
  CrossrefPubMedGoogle Scholar
• 35 Heo JH, Lucero J, Abumiya T. et al. Matrix metalloproteinases increase very early during experimental focal cerebral ischaemia. J Cerebral Blood Flow Metabol 1999; 19: 624-633.
  CrossrefPubMedGoogle Scholar
• 36 Nam HS, Kwon I, Lee BH. et al. Effects of Mesenchymal Stem Cell Treatment on the Expression of Matrix Metalloproteinases and Angiogenesis during Ischaemic Stroke Recovery. PloS One 2015; 10: e0144218.
  CrossrefPubMedGoogle Scholar
• 37 Liu J, Jin X, Liu KJ. et al. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischaemic stroke stage. J Neurosci 2012; 32: 3044-3057.
  CrossrefPubMedGoogle Scholar
• 38 Skuli N, Monferran S, Delmas C. et al. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 2009; 69: 3308-3316.
  CrossrefPubMedGoogle Scholar
• 39 Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischaemic stroke. Neurobiol Dis 2008; 32: 200-219.
  CrossrefPubMedGoogle Scholar
• 40 Hirase T, Staddon JM, Saitou M. et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997; 110: 1603-1613.
  PubMedGoogle Scholar
• 41 Yamashita T, Abe K. Therapeutic approaches to vascular protection in ischaemic stroke. Acta Medica Okayama 2011; 65: 219-223.
  PubMedGoogle Scholar
• 42 Eliceiri BP, Puente XS, Hood JD. et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signalling. J Cell Biol 2002; 157: 149-160.
  CrossrefPubMedGoogle Scholar
• 43 Schwartz MA. Integrin signalling revisited. Trends Cell Biol 2001; 11: 466-470.
  CrossrefPubMedGoogle Scholar
• 44 Kaur J, Zhao Z, Klein GM. et al. The neurotoxicity of tissue plasminogen activator? J Cerebral Blood Flow Metabol. 2004; 24: 945-963.
  PubMedGoogle Scholar
• 45 Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischaemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376-385.
  CrossrefPubMedGoogle Scholar

• Supplementary Material